- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Despite Rhetoric, Obama Has Few Options to Boost Jobs
- US Debating What to Do With Billions of TARP Money Left
- Alleged Florida Ponzi Scheme Could Top $1 Billion
- Forecast From Retailers: Proceed With Caution
- Nordstrom Earnings Miss Forecasts; Shares Take Hit
- Cities With the Most Home Price Reductions
- Housing Recovery 'In Uncharted Territory': HUD Chief
- In Charity Tax Filing, a Real Glimpse of Goldman Sachs
- Intel's Andy Bryant Offers An Explanation
- US 'Actively Working' on Weaker Dollar: Fund Manager
- Options Boil on Biotech Buyout Rumors
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Activision Blizzard's "Modern Warfare 2" Sales Break Records
- 5-Star Manager's 5 Stocks for Changing Markets
- What's The Forecast from Retailers? Proceed With Caution
- Disney's CFO-Theme Park Chairman Executive Swap
- Road Rage Rants
MOST SHARED
- "Friending" Big Pharma
- A Public Hearing That Isn't Public
- Obama Plans Jobs Summit But Not Second Stimulus
- Meet The Leaders of the New Retail Revolution
- Warren Buffett and Bill Gates Share Their 'Optimism' With Eager Columbia Business Students
- Cities With the Most Home Price Reductions
- Disney CFO and Parks Chief to Swap Roles
- Despite Rhetoric, Obama Has Limited Options To Boost Jobs
- Disney Profit, Sales Top Street Forecasts; Shares Jump
Text Size 
Genentech's [DNA
Loading...
()
] asthma drug Xolair should carry the strongest warning possible about the drug's risk of a serious reaction known as anaphylaxis, U.S. health regulators said Wednesday.
The Food and Drug Administration said anaphylaxis -- a severe allergic reaction -- could occur as late as 24 hours after patients take any amount of the drug, also known as omalizumab. The agency added that doctors and patients should be prepared to treat the reaction, which can cause breathing problems, fainting and hives.
In a statement, the South San Francisco-based biotech said it was still discussing the request for a so-called black box warning with the FDA. "The updated wording and its placement in the label is not yet final," the company said.
Genentech is majority-owned by Swiss drugmaker Roche Holding.
Reports of the reaction to Xolair were seen in clinical trials before the drug was approved in 2003 to treat patients with allergy-related asthma, the FDA said. About one in a thousand patients experienced it.
Continued reports of the problem after that prompted the agency's call for the tough warning given "their life-threatening potential, frequency, and the possibility for the delayed onset of anaphylaxis," the agency added.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- They may have wrecked their companies or saved our economy. Tell us what you think.
- Big pharma embraces social media, but how much should a tightly regulated sector say on Facebook or Twitter?
- A European dating site finds lovelorn singles from one country to be consistently uglier. Which is it?
- Contributor David Pogue looks at two of the latest efforts to perfect the digital pocket camera.
- PepsiCo is ramping up its onsite health facilities for workers.
Data is a real-time snapshot *Data is delayed at least 15 minutes